Pharmac prioritized Māori and Pacific patients for access to new diabetes drugs—did they get it right?

The controversial 2021 decision by the government drug-buying agency Pharmac to prioritize Māori and Pacific patients in its funding of two game-changing new diabetes drugs appears to have paid off.

Leave A Comment

Your email address will not be published. Required fields are marked *